Printer Friendly

UCB out-licenses six products to Actient.

M2 PHARMA-July 30, 2010-UCB out-licenses six products to Actient(C)2010 M2 COMMUNICATIONS

30 July 2010 - Belgian UCB SA (EBR: UCB) said Friday it has licensed US marketing rights to six pharmaceutical products to Actient Pharmaceuticals LLC, a US-based specialty pharmaceutical company, with an option for Actient to purchase those products.

Actient is a portfolio company of GTCR, a private equity firm based in Chicago.

In 2009, the six products achieved gross annual sales of approximately USD53m (EUR40.6m). Under the agreement, UCB will receive an upfront payment upon closing as well as future royalty payments.

This transaction is part of UCB's long-term strategy to become the patient-centric global biopharmaceutical leader focused on immunology and neurology, it said.

Products in the transaction include Edex (alprostadil for injection), Theo-24 (theophylline anhydrous), Semprex-D Capsules (acrivastine and pseudoephedrine hydrochloride), Levatol (penbutolol sulfate), Robaxin (methocarbamol tablets, USP) and Dilatrate-SR (isosorbide dinitrate). The product set will form the basis of a commercial platform upon which Actient will continue to license and acquire strategic pharmaceutical assets, UCB added.

(USD1 = EUR0.766)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Company overview
Date:Jul 30, 2010
Words:186
Previous Article:Endologix gains FDA nod for PowerFit Aortic Extensions.
Next Article:Merck's Q2 2010 net income drops to USD752.4m.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters